Zdrowie i gospodarka · 3.07.1995
New Drug Applications; Drug Master Files
The Food and Drug Administration (FDA) is proposing to revise its regulations governing drug master files (DMF's), which are referred to in the review and approval of new drugs and antibiotic drugs for human use. A DMF is a voluntary submission to FDA that may be used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs. The information contained in a DMF may be referred to in support of an investigational new drug application (IND), a new drug application (NDA), an abbreviated new drug application (ANDA), or amendments or supplements to any of these. FDA has defined five distinct categories of submissions that it will accept and maintain, and it has designated these as Type I through Type V DMF's. In December 1992, the Center for Drug Evaluation and Research's (CDER's) Chemistry, Manufacturing, Controls Coordinating Committee (CMCCC) established a DMF Task Force to perform a review and to explore ways of improving all aspects of the system. One of the Task Force recommendations, which was adopted by the CMCCC, was to eliminate Type I DMF's. Type I DMF's contai